AMLN Related Major News
-
Bristol-Myers Squibb (BMY) Acquires Amylin (AMLN) for $31/Share
-
Amylin (AMLN) Bidding Intensifies; Sale Expected in July
-
Amylin (AMLN) Attracting a Host of Other Suitors, Shares Rise
-
Amylin Pharmaceuticals (AMLN) Posts Narrower than Expected Q1 Loss of 23c/Share
-
UPDATE: Amylin (AMLN) Rejected $22/Share Bid from Bristol-Myers (BMY)
-
Amylin Pharma (AMLN) Reports Q4 GAAP Loss of $3.15/Share
-
Amylin Pharmaceuticals, Inc. (AMLN) Posts Q3 Loss of $0.07, Sales Fall Short
-
Amylin Pharma (AMLN) Posts Wider than Expected Q2 Loss; Revs Beat
-
Amylin Pharmaceuticals (AMLN) Reports Q1 Loss of 24c, Misses by 1c
-
Eli Lilly (LLY) and Amylin's (AMLN) Announced BYDUREON Recommended for Approval in Europe
-
Amylin Pharma (AMLN) Posts Q4 adj.-Loss of $0.08
-
Amylin Pharma (AMLN) Posts Q3 GAAP Loss of $0.35; Revs Light
-
Amylin (AMLN), Alkermes (ALKS) and Eli Lilly (LLY) Hit With Request for More Tests from FDA on BYDUREON; Shares Set to Plunge
-
Amylin Pharm (AMLN) Tops Q2 EPS by 1c
-
Amylin Pharma (AMLN) Posts Q1 Loss of $0.27, Beats Views
-
Amylin (AMLN), Eli Lilly (LLY) and Alkermes (ALKS) Receive Complete Response Letter From FDA, But No New Trials Requested
-
Amylin (AMLN) Misses Street's Q4 Views
-
Amylin (AMLN) and Takeda Enter Development Agreement for Obesity Treatments
-
Amylin Pharma (AMLN) Reports Q3 Loss of $0.19, Beats by 10c
-
Amylin (AMLN) Reports Q2 Adj-Loss of $0.36, Misses by 1c
-
Amylin (AMLN) and Eli Lilly (LLY) Study Shows Pancreatitis Risk Is Not Increased with BYETTA
-
Amylin (AMLN) Reports Q1 Loss of $0.34, Misses by 1c
-
Amylin (AMLN) Reports Mixed Q4 Earnings
-
Amylin (AMLN) Reports Q3 Adj-Loss of $0.46, Misses by 4c
-
Amylin (AMLN) Issues Detailed Statement Regarding FDA Alert on BYETTA - Shares Down Almost 9% in After-Hours
-
FDA Issues Warning on Amylin's (AMLN) Byetta: Drug Linked to 6 Pancreatitis Cases -Bloomberg
-
Amylin Pharmaceuticals (AMLN) Misses Q4 EPS by 13c
Back to AMLN Stock Lookup
